Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
September, 2026
September 2026
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
Satish Medakkar: The Importance of Early Recognition in Atypical Hemolytic Uremic Syndrome
Satish Medakkar/ LinkedIn
Aug 2, 2026, 16:24

Satish Medakkar: The Importance of Early Recognition in Atypical Hemolytic Uremic Syndrome

Satish Medakkar, Head of Advanced Analytics and Data Science at Alexion Pharmaceuticals, Inc., shared Alexion Pharmaceuticals, Inc.‘s post on LinkedIn, adding:

“Atypical hemolytic uremic syndrome (or aHUS), also known as complement-mediated thrombotic microangiopathy (or CM-TMA), is an ultra-rare condition where parts of your immune system mistakenly attack the cells lining your blood vessels.

This results in small blood clots, which can reduce blood flow to your kidneys and other vital organs.

Healthcare providers usually diagnose aHUS when you have three conditions together: Microangiopathic hemolytic anemia, Thrombocytopenia, and acute kidney injury.

This combination of conditions makes aHUS difficult to diagnose because the episodes can be triggered by other health conditions.”

Alexion Pharmaceuticals, Inc. shared a post on LinkedIn:

“Timely and accurate diagnosis is critical for people living with atypical haemolytic uraemic syndrome (aHUS), an ultra-rare, rapidly progressive disease that may result in severe organ damage and death.

aHUS is a type of thrombotic microangiopathy (TMA) that is caused by dysregulation of the complement immune system.

aHUS often presents suddenly and frequently develops into a chronic condition with relapses.”

Satish Medakkar: The Importance of Early Recognition in Atypical Hemolytic Uremic Syndrome

Stay updated with Hemostasis Today.

Alexion Pharmaceuticals Atypical Hemolytic Uremic Syndrome Health Hematology Hemostasis Hemostasis News Hemostasis Today Medicine microangiopathic hemolytic anemia Satish Medakkar thrombocytopenia
NewsFeed